Zydus Arm Sentynl Licenses Progeria Drug Progerinin, Strengthens Rare Disease Pipeline
New Delhi: Zydus Lifesciences' wholly owned subsidiary Sentynl Therapeutics has entered into an agreement with Korea-based PRG S&T to license an investigational molecule, Progerinin (SLC-D011), for the treatment of Hutchinson-Gilford…